989 related articles for article (PubMed ID: 19062157)
21. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
[TBL] [Abstract][Full Text] [Related]
22. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
23. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
[TBL] [Abstract][Full Text] [Related]
24. Outcomes following partial nephrectomy by tumor size.
Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
[TBL] [Abstract][Full Text] [Related]
25. Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients.
Marszalek M; Meixl H; Polajnar M; Rauchenwald M; Jeschke K; Madersbacher S
Eur Urol; 2009 May; 55(5):1171-8. PubMed ID: 19232819
[TBL] [Abstract][Full Text] [Related]
26. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland.
Weight CJ; Kim SP; Lohse CM; Cheville JC; Thompson RH; Boorjian SA; Leibovich BC
Eur Urol; 2011 Sep; 60(3):458-64. PubMed ID: 21514718
[TBL] [Abstract][Full Text] [Related]
27. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
[TBL] [Abstract][Full Text] [Related]
28. Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.
Parker WP; Cheville JC; Frank I; Zaid HB; Lohse CM; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2017 Apr; 71(4):665-673. PubMed ID: 27287995
[TBL] [Abstract][Full Text] [Related]
29. Impact of several histopathological prognosticators and local tumour extension on oncological outcome in pT3b/c N0M0 renal cell carcinoma.
Roos FC; Weirich J; Victor A; Elsässer A; Brenner W; Biesterfeld S; Hampel C; Thüroff JW
BJU Int; 2009 Aug; 104(4):461-9. PubMed ID: 19338563
[TBL] [Abstract][Full Text] [Related]
30. Renal cell carcinoma: a clinicopathological follow-up study after radical nephrectomy.
Zubac DP; Bostad L; Gestblom C; Kihl B; Seidal T; Wentzel-Larsen T; Bakke AM
Scand J Urol Nephrol; 2007; 41(3):191-7. PubMed ID: 17469026
[TBL] [Abstract][Full Text] [Related]
31. Observation should be considered as an alternative in management of renal masses in older and comorbid patients.
Beisland C; Hjelle KM; Reisaeter LA; Bostad L
Eur Urol; 2009 Jun; 55(6):1419-27. PubMed ID: 19147267
[TBL] [Abstract][Full Text] [Related]
32. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of tumour size in patients after tumour nephrectomy for localised renal cell carcinoma.
Steiner T; Knels R; Schubert J
Eur Urol; 2004 Sep; 46(3):327-30. PubMed ID: 15306102
[TBL] [Abstract][Full Text] [Related]
34. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Blute ML; Cheville JC; Lohse CM; Frank I; Kwon ED; Weaver AL; Parker AS; Zincke H
Cancer; 2003 Apr; 97(7):1663-71. PubMed ID: 12655523
[TBL] [Abstract][Full Text] [Related]
35. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score.
Thompson RH; Leibovich BC; Lohse CM; Cheville JC; Zincke H; Blute ML; Frank I
J Urol; 2007 Feb; 177(2):477-80. PubMed ID: 17222614
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience.
Klatte T; Patard JJ; Goel RH; Kleid MD; Guille F; Lobel B; Abbou CC; De La Taille A; Tostain J; Cindolo L; Altieri V; Ficarra V; Artibani W; Prayer-Galetti T; Allhoff EP; Schips L; Zigeuner R; Figlin RA; Kabbinavar FF; Pantuck AJ; Belldegrun AS; Lam JS
J Urol; 2007 Jul; 178(1):35-40; discussion 40. PubMed ID: 17521678
[TBL] [Abstract][Full Text] [Related]
37. Prognostic variables to predict cancer-related death in incidental renal tumours.
Bensalah K; Pantuck AJ; Crepel M; Verhoest G; Méjean A; Valéri A; Ficarra V; Pfister C; Ferrière JM; Soulié M; Cindolo L; De La Taille A; Tostain J; Chautard D; Schips L; Zigeuner R; Abbou CC; Lobel B; Salomon L; Lechevallier E; Descotes JL; Guillé F; Colombel M; Belldegrun AS; Patard JJ
BJU Int; 2008 Nov; 102(10):1376-80. PubMed ID: 18727618
[TBL] [Abstract][Full Text] [Related]
38. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience.
Lam JS; Klatte T; Patard JJ; Goel RH; Guillè F; Lobel B; Abbou CC; De La Taille A; Tostain J; Cindolo L; Altieri V; Ficarra V; Artibani W; Prayer-Galetti T; Schips L; Zigeuner R; Pantuck AJ; Figlin RA; Belldegrun AS
Eur Urol; 2007 Jul; 52(1):155-62. PubMed ID: 17316970
[TBL] [Abstract][Full Text] [Related]
39. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
[TBL] [Abstract][Full Text] [Related]
40. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
